YH-32364
- Generic Name
- YH-32364
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT06975410
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath